Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.37
-0.4850-1.08%
Volume:267.71K
Turnover:11.80M
Market Cap:2.72B
PE:10.49
High:44.55
Open:44.36
Low:43.62
Close:44.85
Loading ...

Protagonist Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
25 Feb

Stock Track | Protagonist Therapeutics Soars 7.57% in Pre-Market on Bullish Analyst Views of Pipeline and Partnerships

Stock Track
·
24 Feb

Protagonist Therapeutics: Promising Pipeline and Strategic Partnerships Drive Buy Rating

TIPRANKS
·
24 Feb

Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
24 Feb

Protagonist Therapeutics Faces Financial Risks Amidst Growing Pharmaceutical Pricing Pressures

TIPRANKS
·
23 Feb

Investors in Protagonist Therapeutics (NASDAQ:PTGX) have seen enviable returns of 397% over the past five years

Simply Wall St.
·
22 Feb

Protagonist Therapeutics Poised for Growth with Strong Data Prospects and Robust Financial Position

TIPRANKS
·
22 Feb

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

Reuters
·
22 Feb

BUZZ-Protagonist Therapeutics rises on quarterly profit beat

Reuters
·
21 Feb

Protagonist Therapeutics Shares up 3% After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates

Zacks
·
21 Feb

Protagonist Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
21 Feb

Protagonist Therapeutics' Q4 Earnings, License and Collaboration Revenue Rise

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Shares up 3.9% Premarket After Co Reports Higher Q4 Profit

THOMSON REUTERS
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M

MT Newswires Live
·
21 Feb

Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98

MT Newswires Live
·
21 Feb

Protagonist Therapeutics Inc: Qtrly License and Collaboration Revenue $ 170.6 Mln

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Basic EPS USD 2.11

THOMSON REUTERS
·
21 Feb

Protagonist Therapeutics Q4 Net Income USD 131.674 Million VS. Ibes Estimate USD 22.5 Million

THOMSON REUTERS
·
21 Feb

Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ACCESS Newswire
·
21 Feb